More recently FOXP3 has emerged as a tumour suppressor in breast [23–29] and prostate [28, 30] epithelia, repressing a number of oncogenes including c-myc [30], Ezh2 [25], HER-2/ErbB2 [23] SKP2 [24] and SATB1 [26], while up regulating expression of tumour suppressors p21 [27] and LATS2 [28]. Here, ERBB2 is linked to neoplasm.